ObjectiveTo investigate the therapeutic effect and the mechanism of photodynamic therapy (PDT) on human pancreatic cancer xenograft in nude mice.MethodsThe animal model of human pancreatic cancer was produced by injecting human pancreatic cancer cells SW1990 into the dorsum of nude mice. After photosensitizer hematoporphyrin derivatives(HpD) was injected, the 632.8?nm He Ne laser was used to irradiate the tumor. The tumor′s volume was measured and factor Ⅷ was used for the immunohistochemical staining of the vessel change.ResultsThe tumor growth rate significantly decreased after PDT. Immunohistochemical staining showed significant vessel endothelial cell injury by PDT.ConclusionsPDT has a therapeutic effect on grafted pancreatic cancer possibly by incurring vascular injury.

Pancreatic cancer is highly malignant with a poor prognosis. The resectability and prognosis of early pancreatic cancer are much better than the advanced, so early diagnosis is crucial for saving patients' lives. Because the symptoms of pancreatic cancer are non-specific, most of the patients are misdiagnosed as gastrointestinal or hepatobiliary diseases. Early diagnosis rate of pancreatic cancer can be greatly improved by combined application of tumor marker detection, endoscopic ultrasound, computed tomography, positron emission tomo-graphy, and etc. Early screening of high-risk population has been advocated by the experts, and its value in early diagnosis of pancreatic cancer has been confirmed by relevant studies. The colaboration of multiple pancreatic surgery centers in conducting prospective studies and setting gnidlines for the pancreatic cancer diagnosis, and relevant fundamental reseaches should also be emphasized.

Objective To summarize the diagnosis and treatment of abdominal Castleman disease.Methods The clinical data of 17 patients with abdominal Castleman disease who were admitted to Peking Union Medical College Hospital were retrospectively analysed. Eleven patients had no symptoms, two had an abdominal mass, two had oral ulcers and rash, one had edema and was short of breath and one had dull pain in the upper abdomen and vomiting. Two patients were examined by X-ray, 17 by ultrasound, and 13 by computed tomography(CT). Results Four patients were diagnosed with abdominal Castleman disease by CT preoperatively, and the remaining 13 patients were not conclusively diagnosed. Localized lesions of 14 patients were completely resected,and three patients with multicentric lessions received partial resection or biopsy. The diagnosis of all patients was confirmed by histopathological examination. The expression of CD3, CD20, CD21 and CD34 of 14 patients with hyaline-vascular type was positive, and the expression of CD3, CD68 and PCNA of three patients with plasma-cell type was positive. One patients was lost of follow up, and the remaining 16 patients were followed up for 3-12 months, and neither metastasis nor recurrence was observed. Conclusions The clinical manifestations of abdominal Castleman disease are nonspecific, and therefore, it is difficult to acquire a definite diagnosis before operation. Early complete resection should be applied to patients with localized Castleman disease, while for patients with multicentric Castleman disease, postoperative chemotherapy is necessary for a good prognosis.

Objective To investigate the diagnosis and treatment of mesenteric fibromatosis.Methods We analyzed retrospectively the clinical data including clinical manifestation,treatment and follow-up results of the mesenteric fibromatosis in 11 cases.ResultsNine patients presented with abdominal mass.Two cases were found during other operation occasionally.Before operation,3 cases were misdiagnosed as leiomyosarcoma,1 case as malignant neurilemmoma,1 case as lymphoma.All patients were underwent surgical resection,and were diagnosed as mesenteric fibromatosis by pathology.Following-up,from 7 months to 72 months,2 cases relapsed.Conclusions The clinical feature of mesenteric fibromatosis is nonspecific.It is difficult to make correct diagnosis preoperatively.Surgical resection is the first choice for cure of patients with mesenteric fibromatosis.

The diagnosis and therapy of borderline resectable pancreatic cancer are foci in clinical research.We summarized the status of research on neoadjuvant therapy and discussed the safety and effectiveness of combined vascular resection in borderline resectable pancreatic cancer.We discussed the scope of surgical resection,and evaluated the prognostic markers of post-resectional surgery.

Pancreatic cancer is a highly malignant tumor,the incidence is increasing year by year globally.Due to concealed pathogenesis of which and rapid progress,only 25％ of the patients could receive operation.Adjuvant therapy has become the important methods of improving the prognosis of patients with pancreatic cancer,including chemotherapy and radiotherapy.In recent years,some prospective clinical trials have promoted the development of the adjuvant therapy.New controversy and consensus appear in the treatment of pancreatic cancer.This article reviewed the progress of chemotherapy and radiotherapy for pancreatic cancer based on adjuvant therapy and neo-adjuvant therapy for unresectable metastatic pancreatic cancer and locally advanced pancreatic cancer.

With continuous research of the formation mechanism of chronic pancreatitis with mass in the head of the pancreas and its relation with pancreatic cancer,and steady improvement of the operation safety,the number of operation for the chronic pancreatitis with mass in the head of the pancreas is increasing.On the other hand,with the improvement of the accuracy of preoperative diagnosis,Tru-cut intraoperative biopsy is increasingly applied to patients with negative results of preoperative ultrasonography biopsy,which is important for the surgical procedure selection.With the premise of effective treatment,continous improvement of treatment strategies to the chronic pancreatitis with mass in the head of the pancreas can maximize the benefit of patients.

Pancreatic cancer is one of the most aggressive malignancies in the world.Little progress has been made on the treatment of advanced pancreatic cancer in the past 20 years.miRNAs perform a regulatory role in the determination of the final phenotype of cancer cells,including carcinogenesis,metastatic potential,and chemosensitivity.These features of miRNAs have turned them into one of the most popular and promising fields of scientific and clinical research.Issues such as miRNA toxicity to non-target tissues or cells and lack of proper delivery systems for human pancreatic cancer will be the challenges for the field to overcome.

Pancreatic neuroendocrine tumors(pNETs)have a low prevalence,and may be func-tional as secreting biologically active substance or nonfunctional. With the increased understanding of this disease,new technologies are being developed for diagnosis and treatment. However,surgical excision re-mains the primary therapy for localized tumors and the cure rate is not ideal yet. In choosing the appropri-ate therapy for locally advanced/ metastatic pNETs,medical management strategy should be made in a multidisciplinary context. In addition to chemotherapy,there have been significant advances in targeted mo-lecular therapy.

The special anatomy around the head of pancreas leads to difficulties in arriving at a definitive diagnosis for a pancreatic head mass,the management of which has recently become a hot topic and a challenge for clinicians.Despite recent advances in tumor markers,ultrasound,CT,PET/CT and MRI,some of these pancreatic head masses cannot be diagnosed with certainty.A fine needle aspiration biopsy can be used before operation; however,false negative results not infrequently happen.Based on the reports from domestic and foreign medical literatures published recently,this paper reviewed and discussed the proper treatment strategies when biopsy results from a pancreatic head mass turn out negative.